These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25964202)

  • 1. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
    Talekar M; Ouyang Q; Goldberg MS; Amiji MM
    Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
    Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
    Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
    Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
    Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
    Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
    Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.
    Zhao MD; Li JQ; Chen FY; Dong W; Wen LJ; Fei WD; Zhang X; Yang PL; Zhang XM; Zheng CH
    Int J Nanomedicine; 2019; 14():9453-9467. PubMed ID: 31819443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
    Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
    Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells.
    He D; Zhao XQ; Chen XG; Fang Y; Singh S; Talele TT; Qiu HJ; Liang YJ; Wang XK; Zhang GQ; Chen ZS; Fu LW
    PLoS One; 2013; 8(1):e54181. PubMed ID: 23349819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
    Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
    J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.
    Milane L; Duan Z; Amiji M
    PLoS One; 2011; 6(9):e24075. PubMed ID: 21931642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer.
    Ren F; Chen R; Wang Y; Sun Y; Jiang Y; Li G
    Pharm Res; 2011 Apr; 28(4):897-906. PubMed ID: 21184150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
    Gu J; Fang X; Hao J; Sha X
    Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
    Duan Z; Brakora KA; Seiden MV
    Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.
    Wang SQ; Liu ST; Zhao BX; Yang FH; Wang YT; Liang QY; Sun YB; Liu Y; Song ZH; Cai Y; Li GF
    Oncotarget; 2015 Sep; 6(28):26142-60. PubMed ID: 26317651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells.
    Yang Y; Wang Z; Li M; Lu S
    J Huazhong Univ Sci Technolog Med Sci; 2009 Apr; 29(2):239-42. PubMed ID: 19399413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
    Xu Y; Zhang J; Wu J; Zhong S; Li H
    Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
    Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
    Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines.
    Schöndorf T; Neumann R; Benz C; Becker M; Riffelmann M; Göhring UJ; Sartorius J; von König CH; Breidenbach M; Valter MM; Hoopmann M; Di Nicolantonio F; Kurbacher CM
    Recent Results Cancer Res; 2003; 161():111-6. PubMed ID: 12528803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.